GLP-1 Employer Coverage Tracker: What the 2026 Data Actually Shows

By The Rx Index Research

How many employers cover GLP-1 drugs for weight loss? There is no single number — and the gap between the available numbers is the whole story. In 2025, only about 19% of U.S. firms with 200 or more workers covered GLP-1 agonists primarily for weight loss in their largest health plan, but 43% of firms with 5,000 or more workers did — up sharply from 28% a year earlier, according to KFF. Among the very largest employers, Business Group on Health put weight-loss coverage at 67% in its 2026 survey, while a broad SHRM sample the same year found just 15%. This tracker reconciles those competing figures and documents which named health plans actually changed coverage in 2024–2026, by indication, effective date, and restriction.

Here is the part most coverage misses: in 2026, “does my employer cover it?” stopped being a yes-or-no question. The same plan now routinely covers a GLP-1 for diabetes and excludes it for weight loss. It may cover it above a BMI cutoff and stop at a lifetime fill limit. It may drop it for small groups while selling large groups a paid rider. And the pullback is not hypothetical: according to research by GoodRx, roughly 12 million people were on plans that dropped Wegovy coverage between 2025 and 2026, and about 12 million more were on plans that dropped Zepbound. So the headline percentage means little until you know which employees, which drug, which diagnosis, and which year it describes.

GLP-1 employer coverage statistics: how many employers cover weight-loss drugs?

It depends entirely on which employers you count. Across all large firms (200+ workers), KFF put weight-loss GLP-1 coverage near 19% in 2025; among the very largest and most benefits-advised employers, Business Group on Health put it at 67% in 2026. A broad SHRM sample found only 15% covered the drugs for weight management. Those figures are not in conflict — they measure different populations — and averaging them into one number produces an answer that is wrong for everyone.

Coverage climbs steeply with employer size and with how benefits-sophisticated the surveyed population is. A nationally representative survey of all large firms lands far below a pulse survey of Fortune-500 benefits leaders. Below is every major employer-benefits survey we verified, normalized into shared columns, with each survey’s own definition preserved.

Source: Compiled by The Rx Index Research from KFF (2025 Employer Health Benefits Survey), Mercer (2025 National Survey of Employer-Sponsored Health Plans), Business Group on Health (2026 GLP-1 survey), Willis Towers Watson (2025 Best Practices in Healthcare Survey), Brown & Brown (2025), the International Foundation of Employee Benefit Plans (2025), and SHRM (2026 Employee Benefits Survey). Figures reflect each organization’s own definitions and are not directly comparable. Last verified July 1, 2026.

The verified specifics behind the table: about one in five (19%) large firms offering health benefits covered GLP-1 drugs for weight loss in 2025, and the share of firms with 5,000 or more workers covering them climbed from 28% in 2024 to 43% in 2025. Mercer, surveying a larger-skewing population, found 49% of employers with 500 or more employees covered the drugs in 2025 (up from 44% in 2024 and 41% in 2023) and 66% of employers with 20,000 or more. WTW’s 2025 Best Practices in Healthcare Survey of 417 employers found 57% covered GLP-1s for weight loss, up five points from 52% the year before. IFEBP reported 36% covered GLP-1s for both diabetes and weight loss in 2025 and 55% for diabetes only. Business Group on Health, whose members skew very large, found 67% currently cover the drugs for weight management. And SHRM’s 2026 survey of roughly 5,500 employers found only 15% covered GLP-1s for weight management, even as close to half covered them for type 2 diabetes.

What this tracker documents on top of the surveys. Below, we verify nine specific coverage decisions by named plan sponsors and payers: four confirmed directly from the plan’s or payer’s own published materials (North Carolina State Health Plan, Ohio State University, the State of Ohio, and the University of Michigan), two from carriers’ own coverage documents (Blue Cross Blue Shield of Massachusetts and Blue Cross Blue Shield of Michigan), and three from company-confirmed or reported changes (Cigna’s own-employee plan, HCA Healthcare, and OhioHealth). No single primary source collects these employer-by-employer decisions — they live scattered across HR pages, PDFs, carrier notices, and board materials — which is the reason we assembled them into one dated table.

Why do the coverage numbers range from 15% to 67%?

Because each survey questions a different slice of the market, not because anyone is wrong. Three factors explain almost the entire spread: how a survey defines a “large” employer, whether it samples all firms or only its own large-employer members, and how it separates the diabetes and weight-loss questions. A range of roughly 15% to 67% is what an honest read of the evidence looks like.

Start with size. KFF’s 43% is specifically firms with 5,000+ workers; its 19% spans everyone with 200+. Mercer’s 49% starts the “large” count at 500 employees and reaches 66% only at the 20,000+ tier. Business Group on Health essentially surveys the giants — the employers best able to absorb a four-figure monthly drug — so its 67% describes the top of the market, not the middle.

Next, the sampling frame. KFF draws a broad, nationally representative sample of employers of every kind, which is why its number is the most conservative and the best market-wide baseline. Coalition and consultant surveys (Business Group on Health, WTW) draw from members who opted into a benefits organization — a population that covers more, restricts more precisely, and reports more confidently. SHRM sits at the other end: a broad membership including many small employers, which is why its weight-management figure (15%) is the lowest of the set.

Then, the definition of “coverage.” IFEBP deliberately separates “diabetes only” (55%) from “both diabetes and weight loss” (36%) — the correct distinction, and the one this tracker preserves everywhere. SHRM’s 2026 survey did the same, and the split is stark: close to half of employers cover GLP-1s for type 2 diabetes, but only 15% cover them for weight management. Surveys that blur those two questions produce a middle number that misleads in both directions.

The practical takeaway for anyone writing about this: cite the number that matches the employer you mean. “About 1 in 5 large employers” (KFF, 19%) is right for the market as a whole. “Roughly two-thirds of the very largest employers” (Business Group on Health, 67%; Mercer’s 20,000+ tier, 66%) is right for jumbo firms. “About 15% for weight management specifically” (SHRM) is right for a broad, small-employer-heavy sample. A single blended “average” is the one answer that fits none of them.

What this data shows — and what it doesn’t

These are survey self-reports of plan design, not claims-verified access. They tell you whether a plan covers weight-loss GLP-1s at all — not how many employees actually get approved after prior authorization, and not what happens at the pharmacy counter. The named-plan tracker further down is a documented sample of public decisions, not a census of every U.S. employer.

Two honest limits are worth stating up front. First, “covered” does a lot of work: a plan can technically cover a drug and still gate it behind a BMI floor, prior authorization, a required program, and a lifetime fill cap — which is why the restrictions section below matters as much as the coverage rate. Second, samples differ, so year-over-year trends within one survey are more reliable than comparisons across surveys. We do not blend them, and neither should anyone quoting this page.

How we built this tracker

We compiled the benchmark from each organization’s most recently published survey, preserving its own definitions rather than forcing a single blended figure. For the named-plan tracker, we used only public primary documents — plan sponsors’ own benefits pages, state employee-benefit pages, carrier coverage notices, and board materials — plus reputable reporting where a company confirmed the change on the record. Every row carries a source-quality label and a documented source, and we re-read each source on July 1, 2026.

Our rules, so a reader can reproduce the work:

• Used as evidence: direct employer and plan-sponsor documents, state employee-benefit pages, carrier and PBM coverage notices, board and trustee materials, official survey releases, and government or agency publications.
• Used for language only, never as evidence for a factual claim: forums and social posts. They tell us how people phrase their confusion; they do not establish what a plan covers.
• Excluded from the tracker: third-party aggregations and any employer list we could not tie to a primary or on-the-record source.
• Source-quality tiers below: A = the plan sponsor’s or payer’s own published document, which we read; B = a carrier or PBM document explaining employer-group options, which we read; C = a company-confirmed or reported change we corroborated but for which we did not read a primary plan document.
• Update rule: a row changes only when a public source changes or a newer source supersedes it, and the verification date moves with it.

Which employers and health plans changed GLP-1 coverage?

Real, documented decisions in 2024–2026 span the full spectrum: outright weight-loss exclusions (with diabetes coverage kept), coverage capped by a lifetime fill limit, coverage narrowed to a high BMI threshold, coverage moved off the drug benefit into a reimbursement account, and coverage kept but conditioned on a weight-management program. The through-line is that almost every plan that “cut GLP-1 coverage” cut it only for the obesity indication and kept it for type 2 diabetes.

The table below is our verified sample of named decisions — not a complete list of U.S. employers, but the set we could confirm against a primary or on-the-record source. Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for weight management; Ozempic (semaglutide) and Mounjaro (tirzepatide) are approved for type 2 diabetes.

Source: The Rx Index Research, compiled from each plan sponsor’s or payer’s own materials (NC State Health Plan / NC Department of State Treasurer; Ohio State University HR / OSU Health Plan; Ohio Department of Administrative Services; University of Michigan HR; Blue Cross Blue Shield of Massachusetts; Blue Cross Blue Shield of Michigan) and, for Tier C rows, on-the-record reporting (Reuters; STAT) and corroborating public documentation. All rows verified July 1, 2026. This is a documented sample, not a complete employer census.

A few verified details worth having in front of you. North Carolina’s board voted on January 25, 2024 to remove GLP-1 and GIP-GLP-1 agonists for weight loss effective April 1, 2024, keeping them covered for diabetes, and estimated that continuing coverage would raise premiums by about $48.50 per subscriber per month; the plan’s spending on the drugs was projected to exceed $170 million in 2024. Less than a year later, the plan moved to restore coverage in a more targeted way — a reminder that these decisions are not permanent. Ohio State’s plan states plainly that starting January 1, 2026, GLP-1 medications are covered only when prescribed for type 2 diabetes, with all other uses discontinued and no exceptions or appeals. The University of Michigan’s self-funded plan took a different path: as of May 1, 2024 it covers a lifetime maximum of 24 one-month fills for any combination of GLP-1s used only for weight loss — a benefit-design limit that cannot be appealed and does not touch diabetes coverage or the oral form. Cigna, an insurer itself, confirmed it will stop covering GLP-1 weight-loss drugs including Wegovy and Zepbound in its own employee plan effective July 1, 2026, without affecting diabetes coverage or its outside plans. And Blue Cross Blue Shield of Massachusetts told members that employer groups with more than 100 employees can choose to continue coverage; otherwise, upon renewal starting January 1, 2026, Wegovy, Saxenda, and Zepbound are excluded — even for current users — with the exclusion extending to other FDA-approved uses such as sleep apnea and heart disease.

Tracker changelog

We date every change so freshness is visible. This section records material updates to the tracker; each entry moves the page’s last-verified date.

• July 1, 2026 — Initial publication. All benchmark figures (Table 1) and all nine named-plan rows (Table 2) verified against primary or on-the-record sources on this date.
• Ongoing: New survey editions are added as they publish (KFF around October, Mercer around November, IFEBP around May, Business Group on Health around May, SHRM mid-year). Named-plan rows are re-checked during open-enrollment and renewal cycles, with the source and effective date updated on any change.

Why plan design matters more than the insurer’s name

Two employees can carry cards from the same insurer and have completely different GLP-1 coverage, because the employer’s plan design — not the logo on the card — usually controls. Whether a plan is self-funded or fully insured, whether the employer bought a rider, and when the plan year renews can each flip coverage on or off. This is the single most common mistake we see in stories and posts about GLP-1 access.

The clearest illustration sits inside one state. In Michigan, Blue Cross Blue Shield of Michigan and Blue Care Network stopped covering weight-loss GLP-1s for fully insured large-group commercial members effective January 1, 2025 — yet that change did not touch the University of Michigan, whose self-funded plan sets its own rules and kept covering the drugs under its criteria. Same drugs, same state, opposite outcomes, because a self-funded employer designs its own pharmacy benefit while a fully insured group takes the carrier’s standard benefit unless it buys a rider.

That rider mechanic is why “BCBS covers it” or “Cigna covers it” is an incomplete sentence. Blue Cross Blue Shield of Massachusetts excluded weight-loss GLP-1s as a standard benefit but left the door open for large employers to add them back for an added cost. Cigna dropped the drugs for its own employees while continuing to sell GLP-1 benefit programs to its employer clients. If you want to know your own coverage, the document that governs is your plan’s Summary Plan Description and formulary — not the insurer’s brand.

Why the tracker separates diabetes, weight loss, sleep apnea, and heart disease

Because 2026 plan documents increasingly split coverage by indication, not by drug name. The same molecule can be covered for one diagnosis and excluded for another, so a tracker that lists drugs without listing indications misleads readers. Several plans we verified now exclude a GLP-1 for obesity while continuing to cover it for diabetes — and at least one carrier extended its obesity exclusion to cardiovascular and sleep-apnea uses too.

This is the distinction that trips up almost everyone. Ozempic and Wegovy are both semaglutide; Mounjaro and Zepbound are both tirzepatide. A plan can cover Ozempic (diabetes) all day and never cover Wegovy (obesity) — same active ingredient, different label, different coverage. The newer non-obesity approvals make this sharper: Wegovy is FDA-approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease who have obesity or overweight, and Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Blue Cross Blue Shield of Massachusetts went a step further and excluded the obesity GLP-1s for those other approved conditions too, not just weight loss. Ohio State, the State of Ohio, the University of Michigan, OhioHealth, and both Blue Cross plans above all kept diabetes coverage intact while changing obesity coverage. That is the pattern to report accurately: the cuts are indication-specific, not drug-specific.

A useful way to classify any plan’s status, which we apply throughout this tracker: covered (standard cost-sharing), covered but restricted (BMI floor, prior authorization, program requirement, or fill cap), excluded for weight loss but covered for diabetes or other indications, reimbursement-only (support moved off the drug benefit into an account), or future or approved-but-not-yet-effective.

What restrictions employers add when they keep coverage

Most employers that still cover weight-loss GLP-1s gate access rather than offer it openly. According to KFF, 34% of firms covering the drugs for weight loss required enrollees to meet with a dietitian, case manager, or therapist, or to join a lifestyle program in 2025 — up from just 10% the year before. IFEBP found 78% of covering employers use utilization management, and 96% of those require prior authorization.

The restriction toolkit, drawn from the surveys we verified, recurs in a few forms. Prior authorization is nearly universal among covering employers: 78% use utilization management, and of those, 96% require prior authorization, with some limiting which providers can prescribe. Clinical eligibility rules are close behind: 68% of covering employers use eligibility requirements, including a minimum BMI in 88% of those cases and obesity plus at least one other chronic condition in 60%. Required behavior-change programs are the fastest-growing lever — KFF’s jump from 10% to 34% in a single year is the clearest signal that “coverage with strings” is becoming the norm.

Then there are the harder caps most surveys miss. The University of Michigan’s 24-fill lifetime limit is a structural ceiling: once a member hits roughly two years of injectable weight-loss GLP-1s, coverage ends and cannot be appealed, and the member can then use pretax account funds or switch to a non-GLP-1 weight-loss drug. These are exactly the details a plan member can miss until a pharmacy claim is denied — which is why we log them at the row level.

Why employers are cutting or narrowing coverage

The driver is cost, and it is concentrated. GLP-1 weight-loss drugs list at roughly $1,000–$1,500 a month before rebates, and utilization has outrun forecasts. Among the largest employers covering the drugs, 66% told KFF the impact on their prescription-drug spending was “significant,” and 59% said use ran higher than expected. IFEBP found weight-loss GLP-1s reached 10.5% of employers’ total annual claims in 2025, up from 6.9% two years earlier.

The math is stark at the plan level. According to the Employee Benefit Research Institute, covering GLP-1s could raise employer premiums by roughly 5.3% to 13.8% under real-world cost scenarios, with more than 40% of privately insured adults — over 57 million people — clinically eligible. An Aon analysis reported by SHRM put GLP-1s at roughly 20% of total prescription-drug costs, with total GLP-1 spend up about 50% in 2025; separately, an NFP survey found 51% of employers named GLP-1s the top driver of rising prescription-drug costs. And the trajectory shows in the surveys we verified: IFEBP found weight-loss GLP-1s rose to 10.5% of total annual claims in 2025, up from 8.9% in 2024 and 6.9% in 2023, with about 3 in 10 employers reporting the drugs exceeded 15% of their claims.

North Carolina is the cleanest public case study of the pressure. Its spending on the drugs was projected to exceed $170 million in 2024 and top $1 billion over six years, and continuing coverage would have roughly doubled premiums for individual subscribers. Employers keeping coverage aren’t seeing an obvious short-term payoff, either: the same Aon analysis reported by SHRM found medical costs fell 6–9% within 30 months for diabetes patients who stayed on GLP-1s and 3–7% within 18 months for weight-loss users — real, but slow, and often realized after the average employee has changed jobs.

Is employer GLP-1 coverage growing or shrinking?

The multi-year climb has stalled, and 2026–2027 is turning into a plateau with real pullbacks. Coverage rose steadily among large employers from 2023 through 2025, but Business Group on Health found that only 72% of employers currently covering weight-loss GLP-1s expect to continue in 2027, while 10% expect to drop them — and KFF found just 1% of non-covering firms call themselves “very likely” to add coverage in the next year.

The direction of travel is clear across the trend series we verified. Coverage climbed — Mercer’s large-employer figure went from 41% (2023) to 44% (2024) to 49% (2025), and IFEBP’s “diabetes plus weight loss” share rose from 26% (2023) to 34% (2024) to 36% (2025). But the forward-looking signals point down: among Business Group on Health employers covering the drugs, only 72% said they were likely to continue in 2027 and 10% said they likely would not, while nearly 8 in 10 said the drugs are driving up their healthcare costs, and only 1% of non-covering firms called themselves “very likely” to begin within 12 months. The pullback is already measurable — Mercer reported that 6% of large employers dropped GLP-1 coverage in 2026, and GoodRx research found that roughly 12 million people were on plans that dropped Wegovy and about 12 million on plans that dropped Zepbound between 2025 and 2026.

Source: The Rx Index Research, from Business Group on Health (2026), KFF (2025), Mercer (2026, reported by HR Dive), and GoodRx research (reported by NPR). Verified July 1, 2026.

Are employers required to cover GLP-1s?

Generally, no. No federal law requires employer health plans to cover GLP-1s for either diabetes or weight loss, and self-funded employers have wide discretion over their formularies under ERISA. State mandates are the narrow exception, and as of early 2026 they reach only certain fully insured plans in a small number of states. This section is educational, not legal or benefits advice — your plan’s own documents and a qualified benefits professional are the authorities for your situation.

The legal baseline, per employment-law analyses of the current rules: no federal law requires group health plans to cover GLP-1 drugs for diabetes or weight loss, and employers — especially those sponsoring self-funded plans — retain significant discretion over which drugs to cover. Coverage decisions can also intersect with the Americans with Disabilities Act and HIPAA nondiscrimination rules when a plan singles out one condition, which is one reason employers document their rationale. The table below separates what a rule actually establishes from what it does not.

Source: The Rx Index Research, from employment-law analyses and the North Dakota Insurance Department. As of early 2026, North Dakota was the state most commonly identified by benefits-law analyses as requiring weight-related GLP-1 coverage for certain fully insured individual and small-group plans; other states (for example, New Hampshire) have introduced related bills, and this is a fast-moving area, so confirm current state law before relying on it. Verified July 1, 2026.

Public-payer programs (Medicare and Medicaid) sit outside this employer-plan tracker. For context only: Medicare has historically excluded drugs used purely for weight loss, and federal pricing initiatives are in flux — do not use any public-payer program to infer an employer plan’s coverage, and check CMS directly for current terms.

What changed in the tracker this year?

The verified record shows a clear arc: isolated exclusions in 2024 became a broad wave in 2025 and 2026. Below is the timeline built only from the documented decisions in this tracker — no forecasting, just dated facts.

• January–April 2024: North Carolina State Health Plan votes to exclude weight-loss GLP-1s (effective April 1, 2024), keeping diabetes coverage.
• May 2024: University of Michigan imposes a 24-fill lifetime limit on injectable weight-loss GLP-1s.
• January 1, 2025: Blue Cross Blue Shield of Michigan / Blue Care Network excludes weight-loss GLP-1s for fully insured large groups; OhioHealth removes them from its formulary for weight loss.
• July 1, 2025: The State of Ohio ends weight-loss GLP-1 coverage in its employee plan.
• January 1, 2026: Ohio State University narrows coverage to type 2 diabetes only; Blue Cross Blue Shield of Massachusetts excludes obesity GLP-1s as a standard benefit (rider available for groups over 100).
• July 1, 2026: Cigna ends weight-loss GLP-1 coverage in its own employee plan; HCA Healthcare drops coverage for the 2026 plan year.

One reason employers are moving now is that the alternative to coverage is getting cheaper. Reuters reported that weight-loss drug prices began falling in 2026 with new oral versions, with starting prices around $149 per month for the lowest dose and cash-pay purchases increasingly routed through manufacturer sites. When a covered drug and a cash-pay drug cost within range of each other, the coverage question changes shape.

Limitations: what this tracker does and doesn’t show

This is a documented sample of public plan decisions and published survey data — not a complete census of U.S. employers, and not a substitute for your own plan documents. Public-sector, university, and very large employers are overrepresented here because they publish benefits pages and board materials; most private employers never disclose their pharmacy design.

The honest caveats, stated plainly because they make the data more useful:

• Not every employer is here. Absence from Table 2 means we could not verify a public decision, not that a plan did not change.
• Carrier rules don’t bind every group. A carrier’s standard exclusion may not apply to self-funded employers that use that carrier only as an administrator.
• One employer, multiple plans. Large employers often offer several plans with different pharmacy rules; a single row cannot capture all of them.
• Timing varies. Changes can take effect at plan renewal, not only on January 1, so effective dates differ by group.
• Surveys measure design, not access. A “covered” drug can still be denied at prior authorization or capped by a fill limit.
• Tiers signal confidence. Tier C rows are company-confirmed or reported, not plan-document verified by us; read them accordingly.
• This is educational research, not advice. The documents that control your coverage are your plan’s current Summary Plan Description, formulary, and any written benefit determination. For medical decisions, consult your clinician; for benefits questions, your plan administrator.

How to cite this page

This is a neutral attribution reference, provided so writers and researchers can cite the dataset accurately.

Frequently asked questions

Sources and primary documents

• KFF (Kaiser Family Foundation) 2025 Employer Health Benefits Survey (kff.org) and Peterson-KFF Health System Tracker employer GLP-1 brief.
• Mercer 2025 National Survey of Employer-Sponsored Health Plans (mercer.com); 2026 coverage-drop figure via HR Dive.
• Business Group on Health 2026 GLP-1 survey (businessgrouphealth.org).
• Willis Towers Watson (WTW) 2025 Best Practices in Healthcare Survey (wtwco.com).
• International Foundation of Employee Benefit Plans (IFEBP) 2025 GLP-1 survey release (ifebp.org).
• SHRM 2026 Employee Benefits Survey (shrm.org); findings via HR Dive.
• Employee Benefit Research Institute (EBRI) GLP-1 Coverage and Its Impact on Employment-Based Health Plan Premiums, Issue Brief no. 644 (ebri.org).
• Aon / NFP Aon workforce GLP-1 analysis, as reported by SHRM; NFP employer survey via SHRM.
• GoodRx GoodRx research on plan coverage drops, as reported by NPR.
• North Carolina State Health Plan / NC Treasurer Plan board materials and NC Department of State Treasurer (shpnc.org; nctreasurer.gov).
• Ohio State University OSU HR / OSU Health Plan (hr.osu.edu; osuhealthplan.com).
• State of Ohio (DAS) Ohio Department of Administrative Services (das.ohio.gov).
• University of Michigan U-M HR, Prescription Drug Plan (hr.umich.edu).
• Blue Cross Blue Shield of Massachusetts GLP-1 coverage documents (bluecrossma.org).
• Blue Cross Blue Shield of Michigan / Blue Care Network BCBSM carrier alert; corroborated via University of Michigan HR.
• Reuters / Cigna "Cigna drops coverage of GLP-1 obesity drugs for its own employees" (June 2, 2026).
• STAT / OhioHealth STAT reporting on HCA Healthcare; OhioHealth associate petition and Ohio benefits reporting.
• U.S. Food and Drug Administration Wegovy and Zepbound labeling (fda.gov); North Dakota Insurance Department.

This resource is maintained as an independent reference. Benchmark figures are refreshed as each survey publishes a new edition; named-plan rows are re-checked during open-enrollment and renewal cycles. Report date of last full verification: July 1, 2026.